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Background & Aims  31 
Our aim was to assess long-term metal ion level changes and clinical outcome in patients with a 32 
Birmingham Hip arthroplasty. 33 
Materials and methods 34 
BHR was the most used Hip Resurfacing Arthroplasty (HRA) in Turku University Hospital with 35 
274 hips (233 patients). Additionally, there were 38 BHR-Synergy Total Hip Arthroplasties (THA) 36 
(38 patients). Operations were performed between 2003 and 2010. Median follow up time was 14 37 
years for BHR HRA (range: 0.6-17) and 11 years for BHR THA (range: 4.7-13). A random 38 
coefficient model was used to compare the change between the first and last metal ion 39 
measurement. A Kaplan-Meier estimator was used to assess the survivorship of the BHR HRA and 40 
BHR THA with metal related adverse events (pseudotumor, elevated metal ions above the safe 41 
upper limit, revision due to metallosis), or revision due to any reason as endpoints with 95% 42 
confidence intervals (CI). 43 
Results 44 
In the BHR HRA group, geometric means of Cr and Co levels decreased from 2.1ppb to 1.6ppb and 45 
2.4ppb to 1.5ppb respectively, during a 3.0 year measurement interval. Metal ion levels in the BHR 46 
THA group did not show notable increase. The survivorship of BHR HRA was 66% in 16 years and 47 
34% for BHR THA at 12 years for any metal related adverse event.  48 
Conclusion 49 
Patients with a Birmingham hip device do not seem to benefit from frequent repeated metal ion 50 
measurements. The amount of patients with metal related adverse events was relatively high, but 51 
many of them did not require surgery. 52 
 53 
Introduction 54 
The usage of metal on metal (MoM) hip implants has decreased substantially due to high revision 55 
rates. Nevertheless, approximately 1.5 million MoM hip implants have been implanted worldwide 56 
(1). Despite of the high revision rates associated with metal bearing, majority of these implants are 57 
still in situ and concerns remain regarding the adverse reaction to metal debris (ARMD) and blood 58 
metal ion levels in long term (2).  59 
As for MoM total hip arthroplasties (THA), implant survival of most MoM hip resurfacing 60 
arthroplasty (HRA) brands have been poor compared to conventional bearing surfaces (3).  However, 61 
the Birmingham Hip Resurfacing (BHR HRA, Smith & Nephew, London, United Kingdom) device 62 
is still in scarce use especially in England and Australia (4, 5) due to satisfying outcome compared to 63 
other HRA brands (6, 7). The 10-year overall survival rate for all HRA has been 86 % while BHR 64 
HRA has 91% 10-year survival in Finland (8). 65 
Regulatory authorities worldwide have recommended regular follow-up for MoM hip 66 
arthroplasty patients to detect metal bearing related complications.  Screening tools to detect ARMD 67 
consist of blood metal ion level measurements, hip imaging and patient reported outcome measure 68 
questionnaires. Soft tissue imaging (ultrasound, computed tomography (CT), Metal Artifact 69 
Reduction Sequence (MARS) MRI) have good sensitivity in detecting ARMD, but they are often too 70 
expensive and resource consuming to be used as a sole screening tool. Various safe upper limit (SUL) 71 
blood metal ion levels have been suggested to detect the failing MoM implants (9–13).  However, 72 
recently SUL thresholds have been suggested to be implant specific (14, 15). 73 
Our primary aim was to investigate if there is substantial change in the whole blood metal ion 74 
levels in long term after BHR HRA or BHR THA. Further, we assessed clinical and imaging outcome 75 
for these implants and risk factors for revision surgery to optimize the follow-up. 76 
 77 
 78 
Material and Methods 79 
We performed a retrospective cohort study to assess long term blood cobalt (Co) and chromium (Cr) 80 
levels and clinical outcome in BHR HRA and BHR THA patients operated at our institution. BHR 81 
HRA operations were performed from 2003 to 2010 and BHR THA operations between 2007 and 82 
2009. BHR HRA consists of a trimmed femoral head, capped with a large-diameter modular BHR 83 
head covering and a BHR monoblock acetabular cup. BHR THA consists of a large-diameter modular 84 
BHR head, a large-diameter BHR monoblock acetabular cup and a Synergy femoral stem. 85 
A routine screening program for MoM hips was used at our institution to detect patients with 86 
ARMD. The screening was performed in consensus with the follow-up protocol recommended by the 87 
Finnish Arthroplasty Society (12). The screening included anteroposterior and lateral radiographs of 88 
the hip, WB Cr, and Co measurements and the Oxford Hip Score (OHS) (16). Furthermore, if patients 89 
had poor or moderate OHS score (below 33 points), or elevated WB Cr or Co concentration (above 90 
5ppb), they were referred to MARS-MRI. Patients with poor or moderate OHS or elevated WB ion 91 
measurements were also clinically evaluated by a senior orthopaedic surgeon at our outpatient clinic. 92 
If patients had severe hip symptoms (pain, clicking, swelling) or if a pseudotumor was detected in 93 
MRI, revision surgery was considered. In addition, if an asymptomatic patient had WB metal ion 94 
levels above 10ppb, revision surgery was considered to minimize the risk of Co poisoning.  Patients 95 
who were not admitted to revision surgery were scheduled for annual or biannual visits in our 96 
outpatient clinic. Blood samples from all participating patients were collected and analyzed using the 97 
same methods that we have described earlier in our previous publications (17, 18).  98 
All data was obtained from the Turku University Hospital data lake and electronic medical 99 
records.  100 
In this study, SULs of 4.6 ppb for Cr and of 4.0 ppb for Co were used based on earlier study 101 
by Van Der Straeten (13). The proportion of patients exceeding the SUL values of Cr and Co in the 102 
repeated measurements were reported. 103 
Standard anteroposterior and shoot through lateral radiographs were used to assess 104 
anteversion and inclination angles of the cup. MARS-MRI images were evaluated by a 105 
musculoskeletal radiologist experienced in ARMD related MRI diagnostics. Special attention was 106 
given to soft tissue masses and periarticular fluid collections. Findings were graded using Hart 107 
pseudotumor classification (19).   108 
We used the Oxford Hip Score (OHS) -questionnaire to measure the functional outcomes of 109 
patients with BHR HRA or BHR THA during the follow-up. OHS has a scale of 0 to 48, with 48 110 
being the best patient reported outcome. A score below 26 was considered as a bad outcome, 27-33 111 
points was considered to as a moderate outcome, 34-41 was considered as a good outcome and 42-112 
48 was considered as an excellent outcome. In addition, revision operations and reasons for revision 113 
surgery were checked manually from the patient records. 114 
 115 
Patients 116 
BHR was the most common HRA device at our institution with 233 patients (274 hips). 41 patients 117 
had bilateral operation. Additionally, we identified 38 patients who had a BHR-Synergy THA. 118 
There were no patients with bilateral BHR THA. Median age of the patients was 53 years (IQR=10 119 
years, range 18-76). 89 (33%) were female. The follow-up data from the patients was collected until 120 
November 2019 or eventual death. The number of deceased patients during the follow-up was 23. 121 
Median follow-up time for BHR HRA and BHR THA was 14 years (range 0.6-17) and 11 years 122 
(range: 4.7-13), respectively. Patient characteristics are presented in Table 1.  [insert Table 1.] 123 
 124 
223 patients (193 BHR HRA and 30 BHR THA) with 1 or more metal ion measurements 125 
during the follow-up were identified. 171 BHR HRA and 19 BHR THA patients had 2 or more metal 126 
ion measurements (BHR HRA: median = 2 (range: 2-6), BHR THA: median = 3 (range: 2-5)). If a 127 
patient had more than 2 consecutive metal ion measurements, the first and the last of the 128 
measurements were used to assess change. The median time from the first metal ion measurement 129 
(initial measurement) to the last (control measurement) was 3.0 years (range 0.8-6.8 years) and it was 130 
considered as the measurement interval. The mean time from the index operation to the initial metal 131 
ion measurement was 7.5 years (range 3.9-14). For staged bilateral patients this was calculated from 132 
the date when the second hip was operated. The follow-up data was collected until 28.10.2019. 12 133 
patients with BHR HRA did not have inclination or anteversion angle data. Further, 151 hips had 134 
been imaged using MARS-MRI and 192 patients (175 BHR HRA and 17 had BHR THA) had 135 
completed the OHS questionnaire postoperatively.   136 
 137 
Ethics 138 
The study was based on the national recommendation for systematic screening of MoM Hip 139 
Arthroplasty patients given by the Finnish Arthroplasty Society (2014). It was a register study, and 140 




The individual change between two consecutive metal ion measurements from the same patient was 145 
modelled using a random coefficient model. Log-transformed ion values were used in conditional 146 
models due to positively skewed distribution of ion levels. Results were reported as geometric means 147 
and medians with range at the initial and control measurements for better interpretation. Spaghetti 148 
plots for naturally log-transformed ion values were generated to visualize individual changes in ion 149 
levels. A Kaplan-Meier estimator was used to analyze the overall survivorship function, with revision 150 
surgery as the endpoint with 95% confidence interval (CI). A separate Kaplan-Meier analysis was 151 
performed to assess the survivorship of the BHR HRA and BHR THA patients with metal related 152 
adverse events (pseudotumor, elevated metal ions above the SUL, or revision due to ARMD) as 153 
endpoints with 95% CI. Wilcoxon rank sum test was used to compare the OHS scores and ion levels 154 
of patients with a radiologically diagnosed pseudotumor and patients without a radiologically 155 
diagnosed pseudotumor. 156 
 Hazard ratios (HR) with 95% CI for metal related adverse events (pseudotumor, elevated 157 
metal ions above the SUL, or revision due to ARMD) were assessed using multivariable Cox 158 
regression analysis, adjusting for potential contributory factors age, sex, bilateral surgery, 159 
inclination angle and anteversion angle. None of these variables were considered to be along causal 160 
pathway from exposure to outcome but were considered as confounders. The proportional hazards 161 
assumption for Cox analysis was evaluated with a statistical test based on scaled Schoenfeld 162 
residuals (20).  163 
 P-values lower than 0.05 in a 2-tailed test were considered statistically significant in all analyses. All 164 
statistical analyses were carried out using the R statistical computing environment version 3.5.3  165 
R packages survival (version 3.2-10) and ggplot2 (version 3.3.3) were used for survival analysis and 166 
visualizations, respectively (21).  167 
 168 
Results 169 
Geometric mean of Co decreased from 2.1 ppb (range 0.2-122) to 1.6 ppb (range 0.1-100, p<0.001) 170 
and similarly the geometric mean of Cr decreased from 2.4 ppb (range 0.7-56) to 1.5 ppb (range 0.2-171 
63, p<0.001) during the 3.0 years measurement interval in the BHR HRA group. Metal ion levels in 172 
the BHR THA group did not show notable increase. Differences in metal ion levels and p-values are 173 
demonstrated in Table 2.  [insert Table 2.] 174 
In the whole cohort, Co values were above the SUL in 55 patients (25%) in the first 175 
measurement and above the SUL in 41 patients (22%) in the last measurement. In a similar manner, 176 
Cr values were above the SUL in 32 patients (14%) in the first measurement and above the SUL in 177 
21 patients (11%) in the last measurement. Overall, 26 patients had ion levels above 10 ppb during 178 
follow-up and 12 of them eventually had a revision (10 patients had a revision due to ARMD). 179 
Change of individual Co and Cr values are presented in Figure 1. [insert Figure 1.] 180 
  Out of the 151 hips with MARS-MRI imaging we identified 62 hips (41%) with 181 
radiologically diagnosed pseudotumor. Of these, 24 were Hart 1, 10 Hart 2A, 23 Hart 2B, and 5 Hart 182 
3.  If patients had repeated MARS-MRI imaging, we reported the one with the highest grade 183 
pseudotumor. 18 hips with a pseudotumor had more than one MARS-MRI done. In 8 hips the size 184 
and grading of the pseudotumor remained similar. In 1 hip the pseudotumor was no longer visible in 185 
the repeated MARS-MRI. In 3 hips pseudotumors had decreased in size in the repeated MARS-MRI. 186 
On the other hand, in 5 hips the pseudotumor had increased in size in the repeated MRI, and in 1 of 187 
these hips grade of the pseudotumor was higher in the repeated MARS-MRI. Additionally, 26 hips 188 
had repeated MARS-MRI with normal initial MARS-MRI images.  New pseudotumor was detected 189 
in 5 hips, while the repeated MARS-MRI was normal in 21 hips. Patients with a radiologically 190 
diagnosed pseudotumor presented with significantly higher Co (p<0.001) and Cr values (p<0.001) 191 
than patients without a pseudotumor. Patients without a radiologically diagnosed pseudotumor had a 192 
median Co of 1.8ppb (interquartile range [IQR]=2.4) and median Cr of 2.2ppb (IQR=1.8) while 193 
patients with a radiologically diagnosed pseudotumor had median Co of 5.8ppb (IQR=10.5) and 194 
median Cr of 4.2ppb (IQR=4.7). 195 
 196 
Implant survival with revision for any reason as the end point 197 
We had an overall implant survival of 83% in 16 years for BHR HRA and 87% for BHR THA 198 
at 12 years with revision for any reason as the endpoint. 40 hips of 274 were revised in the BHR HRA 199 
group and 5 of 38 hips were revised in the BHR THA group (Figure 2).  ARMD was the most common 200 
reasons for revision in both BHR HRA and BHR THA groups (10 (25%) and 3 hips (60%), 201 
respectively). Other reasons for revision in BHR HRA group were: periprosthetic fracture (7 hips), 202 
loosening of the cup (7 hips), loosening of the femoral component (5 hips), mechanical impingement 203 
(4 hips), infection (2 hips), implant mal-alignment (2 hips), pain (1 hip), grossly elevated metal ions 204 
(1 hip) and leg length discrepancy (1 hip). Other reasons for revision in BHR THA group were 205 
infection and pain (1 hip each). [insert Figure 2.] 206 
 207 
Survival with any metal related adverse event (pseudotumor in MARS MRI, elevated metal ions above 208 
the SUL, or revision due to ARMD) as the end point 209 
The overall survival of the hips in terms of metal related adverse events (pseudotumor, 210 
elevated metal ions above the SUL, or revision due to ARMD) was 63% at 16 years. For BHR HRA 211 
separately it was 66% in 16 years and for BHR THA it was 34% at 12 years from the operation 212 
(Figure 3). The total number of metal related adverse events during our follow-up was 98. [insert 213 
Figure 3.] 214 
 215 
Overall, 175 out of 192 patients (91%) had good- to excellent OHS scores postoperatively. In 216 
BHR HRA group 161 patients out of 175 reported a good- to excellent outcomes, while only 6 patients 217 
(4.9%) reported having a bad outcome. In BHR THA group 13 patients (77%) out of 17 had an 218 
excellent outcome and 3 patients (20%) reported a bad outcome. Patients without a radiologically 219 
diagnosed pseudotumor (n=148) had a median OHS score of 46 (IQR=7, range 2-48), while patients 220 
with a radiologically diagnosed pseudotumor (n=44) had a median OHS score of 44 (IQR=9, range 221 
3-48). The difference between OHS scores was statistically significant (p=0.03). 222 
 223 
In Cox multivariable regression analysis cup retroversion was associated with increased risk 224 
of adverse events when compared to cups that were in anteversion with a HR of 3.9 and the difference 225 
was statistically significant (p<0.0001).  Cox multivariable regression analysis data with 95% CI is 226 




The aim of this study was to assess long term blood Co and Cr levels and clinical outcome for patients 231 
with BHR HRA or BHR THA. WB Co and Cr levels in BHR patients stayed mostly below the SUL. 232 
Further, we noted a statistically significant decrease in both Co and Cr levels during median follow-233 
up time of 14 years in BHR HRA group. Metal ion levels in BHR-THA group did not show notable 234 
increase during a follow-up of 11 years.  The amount of patients with metal related adverse events 235 
was relatively high, but many of them did not require surgery. 236 
 237 
Our results regarding decreasing ion level trends are in line with previous studies. Van der 238 
Straeten et al. studied WB Co and Cr change in patients with well-functioning BHR implants. Overall 239 
Co and Cr levels decreased significantly in their cohort at 10 to 13 years in asymptomatic patients 240 
(22). Also, patients with unilateral or bilateral ReCap-M2A-Magnum MoM THA had decreasing ion 241 
levels in long term follow-up. Authors discussed that these patients might not benefit from repeated 242 
metal ion measurements on as short as a two year interval (17, 18). Even when the high-risk Articular 243 
Surface Replacement (ASR) implants were assessed, Reito et al. reported that patients with a 244 
unilateral ASR HRA might not benefit from repeated metal ion measurements on a one-year interval. 245 
However, high risk ASR XL THA patients did benefit from repeated metal ion measurements in order 246 
to detect patients with ARMD (9). National guidelines recommend regular WB metal ion 247 
measurements in the follow up of patients treated with MoM implants. However, performing regular 248 
metal ion measurements for all MoM hip patients is both expensive and resource consuming (12, 23). 249 
Based on our study and earlier literature 2-year interval seems rather short for repeated ion 250 
measurements in patients with BHR HRA or BHR THA device. For long term follow-up for example 251 
5-year interval might be more appropriate. 252 
MARS-MRI in our study was performed only to patients with poor or moderate OHS -scores, 253 
symptomatic hip, or elevated WB Co or Cr ion levels. Thus, the reported high prevalence of 254 
pseudotumor in MARS-MRI does not represent the whole cohort of patients. Ideally, we would have 255 
had MARS-MRI images from all the patients with a BHR hip implant. As expected, levels of both 256 
Co and Cr were higher in patients with a radiologically diagnosed pseudotumor. Only 3 out of 257 
seventeen pseudotumors increased in size in repeated MRI. Relatively high prevalence of 258 
pseudotumors in MARS-MRI of BHR patients have been reported previously but the data concerning 259 
the subject is scarce (19). Bisschop et al reported  a prevalence of 28% for pseudotumors in CT scans 260 
of BHR HRA patients, and majority of these (72.5%) were asymptomatic (24).    261 
Regarding to the OHS score, majority of the patients in our study reported good to excellent 262 
scores after the BHR implantation. Comparably, Matharu and colleagues reported a total of 1394 263 
OHS questionnaires with excellent outcomes, preoperative OHS score improving from preoperative 264 
19 to 46 at the latest visit (25). In our study, patients with a radiologically diagnosed pseudotumor 265 
reported inferior OHS-scores when compared to patients without a radiologically diagnosed 266 
pseudotumor, although the difference was not necessarily clinically significant.  Unfortunately, our 267 
patients do not have pre-operative OHS values. Kwon et al. found out that asymptomatic MoM HRA 268 
patients with a pseudotumor may have even lower OHS scores than patients without a pseudotumor 269 
(41 and 47 points, respectively) (26). However, this correlation between symptoms and pseudotumor 270 
incidence is not clear (27).  271 
The survival of BHR HRA was 83% at 16 years and that of BHR THA 87% at 12 years in our 272 
material. This is in line with Finnish Arthroplasty Register which reports a revision rate of 13 % for 273 
BHR at 15 years (7). The Australian registry reports a slightly better survival with BHR HRA with 274 
7% revision rate at 10 years and 10% at 15 years (28). In a similar manner, NJR reports a revision 275 
rate of 8% at 10 years and 11% at 15 years for BHR HRA (6). 276 
 In the short- to mid-term follow up BHR HRA and BHR THA seemed to have equally good 277 
survival rates with 95% and 97 % at 6 years, respectively (29). However, in the long term follow-up 278 
BHR THAs revision rates increase to 18% at 10 years, which is higher than for majority of the other 279 
MoM THA or HRA brands (7, 28). We did not notice this increased revision rate compared to BHR 280 
HRA in the current study. The amount of BHR THA was rather small, though. Due to the previously 281 
reported high risk of ARMD and revision surgery the implantation of BHR THA is no longer 282 
recommended (30). 283 
Sole revision rate might not tell the whole truth about adverse events or functional failure. 284 
Therefore, we assessed separately survival with any metal related adverse event (pseudotumor in 285 
MARS-MRI, elevated metal ions above the SUL, or revision due to ARMD) as the end point. It seems 286 
that we had considerably metal related adverse events, although most of them did not require revision 287 
surgery. This is especially true with the BHR THA. 288 
Cup positioning has been reported to be a risk factor for increased wear and metal bearing 289 
related complications. Excessive anteversion, insufficient anteversion or increased cup inclination 290 
increase the risk of posterior edge loading and impingement in MoM implants, which can lead to 291 
excess wear (31, 32). In our study only the retroversion of the acetabular cup was associated with an 292 
increased risk for metal related complications, although bilateral surgery or cup inclination did not 293 
have an effect.  There is some evidence that pseudotumors do not have to necessarily be associated 294 
with high wear or increased metal ion levels and they can occur in well positioned implants, 295 
suggesting that patient susceptibility has an important role in the development of pseudotumors 296 
(33).  297 
We acknowledge that our study had several limitations. First, the measurement interval was 298 
relatively short. Longer follow up might change the course. Another limitation was that some patients 299 
with poor clinical outcome may have been revised before any metal ion measurements were done. 300 
Further, all patients did not go through MARS-MRI or fill in OHS questionnaire which might have 301 
skewed the results. Our results are implant specific, and therefore not generalizable to other MoM 302 
devices. In the current study we used SUL values suggested by Van Der Straeten et al. (2013) for 303 
unilateral HRA implants. We used this SUL value for both unilateral and bilateral BHR HRA and 304 
unilateral BHR THA patients for better interpretability.  305 
 306 
Conclusion 307 
We found that WB metal ion levels decrease during the long-term follow-up in BHR patients. Patients 308 
with a well-functioning BHR hip may not necessarily benefit from routine metal ion measurements 309 
on a 2-year interval. The amount of patients with a metal related adverse events was relatively high, 310 
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